Emergent BioSolutions

Emergent BioSolutions is an American multinational biopharmaceutical company based in Gaithersburg, Maryland.

A Killer Enterprise: How One of Big Pharma’s Most Corrupt Companies Plans to Corner the Covid-19 Cure Market One of the most politically-connected yet scandal ridden vaccine companies in the United States, with troubling ties to the 2001 anthrax attacks and opioid crisis, is set to profit handsomely from the current Coronavirus crisis. by Whitney Webb - April 9, 2020

One of their biggest proponents of expanding BioPort’s contracts was working for HHS at the time — Jerome Hauer, a man who not only had foreknowledge of the anthrax attacks, but had also participated in the Dark Winter simulation that would also predict those same attacks just months prior. Hauer would, months later, be appointed to a newly created position at HHS, one which oversaw the new biodefense stockpile from which BioPort would be a major beneficiary.

BioPort would be then renamed and repackaged as Emergent Biosolutions in 2004. It would then hire even more well-connected lobbyists and add several big names from government and the private sector to its board. One of these “big names” was none other than Jerome Hauer, who was added to Emergent’s board soon after leaving HHS. Hauer still remains a company director and sits on three of its corporate governance committees.

Not only did Emergent Biosolutions profit from national anthrax fears, they would also cash in on subsequent pandemic panics and later receive substantial backing from the Bill Gates-backed Coalition for Epidemic Preparedness Innovations (CEPI). They would then turn their attention to the still-raging opioid addiction and overdose crisis by buying rights to the only drug approved for treating opioid overdoses at the scene while also suing any and all generic producers of this crucial, life-saving treatment.

Given its history, it should come as little surprise that Emergent Biosolutions is now set to profit from the Coronavirus (Covid-19) crisis. They are particularly well-suited to make record profits off of Covid-19, as they are backing not one, but two, vaccine candidates as well as an experimental blood plasma treatment already approved for trials in New York state, thanks in part to Jerome Hauer’s old boss, New York governor Andrew Cuomo. As noted in a previous article for The Last American Vagabond, the other main companies developing Covid-19 vaccines in the U.S. are strategic partners of the controversial Pentagon research agency DARPA, which has become increasingly aligned with HHS in recent years thanks to another Dark Winter participant, Robert Kadlec.

In this second installment of the series “Engineering Contagion: Amerithrax, Coronavirus and the Rise of the Biotech-Industrial Complex,” Emergent Biosolution’s rise to prominence, made possible through acts of blatant corruption and the public-private revolving door, will be explored. The clear nexus between Big Pharma, Government and University-affiliated “Biosecurity Centers” offers a startling look into the Biotech-Industrial Complex that has long dominated U.S. biodefense policy and is now guiding much of the U.S. government’s response to the Coronavirus crisis. ¹⁾

Sanofi offloads smallpox vaccine business to Emergent BioSolutions in $125M deal

by Angus Liu | Jul 18, 2017

Emergent BioSolutions is set to add the only FDA-approved smallpox vaccine to its portfolio through a $125 million deal with vaccine giant Sanofi Pasteur.

The agreement means Emergent will inherit an existing CDC contract to build the national stockpile. That 10-year, $425 million contract has around $160 million left to be fulfilled before it ends in 2018. Emergent expects to negotiate a multiyear renewal as part of its involvement in the U.S. government’s counter-bioterrorism effort.

Emergent CEO Daniel Abdun-Nabi said in a statement that he expects the deal to contribute meaningful revenue growth to the company next year and help it reach a $1 billion revenue goal by 2020. But that depends on the FDA’s approval of a Canton, Massachusetts-based live viral manufacturing facility. ²⁾

In June 2020, AstraZeneca and Emergent partnered to manufacture their COVID-19 vaccine product.^{3) 4)} In July 2020, Emergent was awarded a five-year contract with Johnson & Johnson to manufacture a core component of their COVID-19 vaccine product.⁵⁾

FDA orders shutdown at Emergent's troubled plant 2 weeks after handing J&J the keys April 19, 2021 by Kevin Dunleavy

Johnson & Johnson’s takeover of COVID-19 vaccine manufacturing at an error-prone Emergent BioSolutions plant in Baltimore didn’t last long.

Two weeks after the U.S. stepped in and handed control of vaccine manufacturing at the plant to J&J, Emergent agreed to stop producing drug substance there.

In March, the factory had to discard up to 15 million vaccine doses when it mixed up materials for the J&J and AstraZeneca vaccines. The New York Times reported an additional batch of between 10 million and 15 million doses of the AZ vaccine was lost last November because of suspected contamination at the plant. ⁶⁾